What are the indications, recommended dosing, dose adjustments, contraindications, monitoring parameters, and common adverse effects for Olaparib (a PARP inhibitor)?

Olaparib: Clinical Overview

Olaparib is a PARP inhibitor indicated primarily for maintenance therapy in ovarian cancer patients with BRCA mutations or homologous recombination deficiency, dosed at 300 mg orally twice daily (tablet formulation), with dose reductions to 250 mg or 200 mg twice daily as needed for toxicity management.

Indications

Ovarian Cancer - First-Line Maintenance

• Stage III-IV high-grade serous or endometrioid ovarian cancer in patients achieving CR/PR to first-line platinum-based chemotherapy 1
• BRCA1/2 germline or somatic pathogenic variants (strong indication) 1
• Duration: 2 years of maintenance therapy 1

Ovarian Cancer - Recurrent Disease Maintenance

• Platinum-sensitive recurrent disease (second-line or greater) in patients who have not previously received a PARP inhibitor and achieved CR/PR to platinum-based therapy 1
• Effective regardless of BRCA mutation status, though greatest benefit in BRCA-mutated patients 1
• Continue until disease progression or unacceptable toxicity 1

Combination Therapy

• Olaparib + bevacizumab may be offered for stage III-IV disease with BRCA mutations and/or genomic instability (Myriad myChoice CDx positive) in patients responding to chemotherapy plus bevacizumab 1
• Recent evidence suggests pembrolizumab + olaparib combination shows promise in BRCA non-mutated advanced ovarian cancer, though this represents emerging data 2

Prostate Cancer

• Metastatic castration-resistant prostate cancer with BRCA mutations benefits from olaparib combined with abiraterone 3

Recommended Dosing

Standard Dose

• 300 mg orally every 12 hours (tablet formulation) 1, 4
• This represents 4 tablets daily versus the older capsule formulation requiring 16 capsules daily 4, 5

Dose Adjustments

For Renal Impairment:

• Mild renal impairment (CrCl 51-80 mL/min): No dose adjustment needed 6
• Moderate renal impairment (CrCl 31-50 mL/min): Reduce to 200 mg twice daily and monitor carefully 6
• The 44% increase in drug exposure with moderate renal impairment necessitates this reduction 6

For Toxicity:

• First dose reduction: 250 mg twice daily
• Second dose reduction: 200 mg twice daily 4
• Real-world data demonstrates that dose reduction to 500 mg or 400 mg daily does not adversely affect progression-free survival or overall survival 7
• Approximately 65% of patients on 400 mg tablets twice daily eventually require dose reduction to 300 mg 4

Contraindications

• Prior PARP inhibitor therapy in the same treatment line (though retreatment studies are ongoing) 1
• Pregnancy (implied by mechanism and cancer treatment context)
• Avoid substituting olaparib in regimens designed for other PARP inhibitors without established safety data 1

Monitoring Parameters

Hematologic Monitoring

• Complete blood count at baseline and regularly during treatment
• Anemia is the most common grade 3-4 adverse event (22.7% in elderly patients) 8
• Neutropenia occurs in approximately 23% of patients (grade 3-4) 2
• Thrombocytopenia is less common with olaparib compared to niraparib 8

Renal Function

• Creatinine clearance at baseline and periodically, particularly in patients with borderline renal function 6

Clinical Assessment

• CA-125 levels if applicable for ovarian cancer monitoring
• Performance status and symptom assessment
• Most dose reductions, interruptions, and discontinuations occur within the first 6 months of therapy 8

Long-term Safety

• Monitor for myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) risk, particularly with prolonged therapy 1

Common Adverse Effects

Most Frequent (Any Grade)

• Fatigue (35.7% in standard dose patients) 7
• Nausea (33.3%) 7
• Anemia (very common, 22% grade 3-4) 8
• Neutropenia (23% grade 3-4) 2

Grade 3-4 Adverse Events

• Anemia: 22% with olaparib monotherapy 8
• Neutropenia: 23% in combination with pembrolizumab 2
• Febrile neutropenia: 4% in combination regimens 2

Serious Adverse Events

• Treatment-related serious adverse events occur in approximately 24% of patients receiving olaparib combinations 2
• Cerebral hemorrhage, cholangitis, hemophagocytic lymphohistiocytosis, and colitis have been reported as fatal treatment-related events (rare, <1%) 2

Key Clinical Pearls

Formulation Matters

The tablet formulation (300 mg twice daily) has improved bioavailability compared to the capsule formulation (400 mg twice daily), reducing pill burden from 16 to 4 tablets daily while maintaining equivalent or superior drug exposure 4, 5.

Dose Reduction Does Not Compromise Efficacy

Real-world evidence demonstrates that patients requiring dose reduction to 500 mg or 400 mg daily maintain similar progression-free survival and overall survival outcomes 7. This is reassuring for managing toxicity.

Elderly Patients

PARP inhibitors are generally well-tolerated in elderly patients (≥65 years), with long-term use being feasible after the initial 6-month period 8. Niraparib shows lower discontinuation rates than olaparib in this population 8.

Predictive Factors for Benefit

In first-line maintenance, R0 resection at initial surgery, BRCA mutation status, and CA-125 ≤10 U/mL before PARP inhibitor treatment independently predict longer progression-free survival 8.

Avoid Regimen Substitution

Do not substitute olaparib in the veliparib chemotherapy combination regimen, as safety, dosing, and duration have not been established for this approach 1. When olaparib is combined with carboplatin/paclitaxel, carboplatin dose modification and olaparib exposure attenuation are required 1.